Also known as alvociclib, this wide spectrum CDK inhibitor targets CDK1, CDK2, CDK4, CDK6, CDK7 and CDK9 and displays antiproliferative efficacy in several solid tumours and sarcomas, as well as in leukaemia, lymphoma and multiple myeloma [299,300,301,302,303,310]. The gene discussed is CDK2; the disease is leukemia.